Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-06
2006-06-06
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S092000
Reexamination Certificate
active
07056914
ABSTRACT:
The present invention relates to Benzoxazinone-derived compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.
REFERENCES:
patent: WO 95/02405 (1995-01-01), None
patent: WO 95/28397 (1995-10-01), None
patent: WO 97/19682 (1997-06-01), None
patent: WO 97/20823 (1997-06-01), None
patent: WO 97/25992 (1997-07-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 98/24768 (1998-06-01), None
patent: WO 98/35957 (1998-08-01), None
patent: WO 98/40356 (1998-09-01), None
patent: WO 99/40091 (1999-08-01), None
patent: WO 00/20376 (2000-04-01), None
patent: WO 01/07409 (2001-02-01), None
patent: WO 01/13917 (2001-03-01), None
patent: WO 01/44213 (2001-06-01), None
patent: WO 01/64675 (2001-09-01), None
patent: WO 02/094825 (2002-11-01), None
Hackh's Chemical Dictionary (Fourth Edition) 1969, pp. 25 and 193.
http://www.encyclopedia.com/html/a1/aliphati.asp downloaded on Apr. 6, 2005.
William, et al. “1-{1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperdin-4-yl}-4H-3,1-benzoxazin-2(1H)-one (L-371,257): A New, Orally Bioavailable, Non-Peptide Oxytocin Antagonist”, J. Med. Chem., 1995, 38, pp. 4634-4636.
Williams, et al., “Nonpeptide Oxytocin Antagonists: Analogs of L-371,257 with Improved Potency”, Bioorganic & Medicinal Chemistry Letters, 9, (1999), pp. 1311-1316.
“Multiple Receptors For Neuropeptide Y In The Hippocampus: Putative Roles In Seizures And Cognition”, Redrobe et al., Brain Research Interactive, 848, 1999.
“Neuropeptide Y: A Possible Role In Hypertension?”, Michel et al., Journal of Hypertension 1995.
“Identification Of A Novel Hypothalamic Neuropeptide Y Receptor Associated With Feeding Behavior”, Hu et al., Journal of Biological Chemistry, vol. 271, No. 42, 1996.
“A Receptor Subtype Involved In Neuropeptide-Y-Induced Food Intake”, Gerald, et al., Letters to Nature, vol. 382, 1996.
“1-{1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl}-4H-3,1-benzoxazin-2(1H)-one (L-371,257): A New, Orally Bioavailable, Non-Peptide Ozytocin Antagonist”, Williams et al., Jnl. Med. Chem., 38, 1995.
“Autoradiographic Reevaluation Of The Binding Properties Of125I-[Leu31,Pro34]Peptide YY and125I-Peptide YY3-36to Neuropeptide Y Receptor Subtypes In Rat Forebrain”, Gobbi et al., Journal of Neurochemistry, 1999.
“Development of Orally Active Oxytocin Antagonists: Studies on 1-(1-{4-[1-(2-Methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2-methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and Related Pyridines”, Bell et al., J. Med. Chem., 41, 1998.
Angeles Fisas Escasany Maria
Aurelio Castrillo Perez Jose
Dordal Zueras Alberto
Frigola Constansa Jordi
Jover Antoni Torrens
Berch Mark L
ESTEVE Laboratorios Dr. Esteve S.A.
Habte Kahsay
Perman & Green, LLP.
LandOfFree
Benzoxazinone-derived compounds, their preparation and use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoxazinone-derived compounds, their preparation and use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoxazinone-derived compounds, their preparation and use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3678910